Welcome to our dedicated page for X4 Pharmaceuticals SEC filings (Ticker: XFOR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
X4 Pharmaceuticals, Inc. filings document a rare-disease biopharmaceutical issuer with commercial activity for XOLREMDI and development work around mavorixafor. Its 8-K reports cover operating and financial results, material agreements, restructuring actions, executive and board changes, and capital-structure updates involving common stock, pre-funded warrants, registration rights, and equity purchase arrangements.
Proxy materials describe shareholder voting matters, board composition, committee assignments, executive compensation, equity awards, and governance procedures. The filing record also includes disclosures tied to the company’s inducement and equity incentive practices, financing arrangements, and formal reporting of material corporate events.
X4 Pharmaceuticals amendment to Schedule 13G/A reports that Perceptive Advisors, Joseph Edelman and Perceptive Life Sciences Master Fund, Ltd. each beneficially own 6,889,163 shares, representing 7.3% of Common Stock based on 94,319,696 outstanding shares as of May 1, 2026. The filing states the Master Fund directly holds 6,737,648 shares and 151,515 Warrants immediately exercisable for Common Stock, subject to a Beneficial Ownership Limitation that caps ownership at 9.99%.
The reporting persons disclose shared voting and dispositive power over the reported shares and note Perceptive Advisors acts as investment manager to the Master Fund, with Joseph Edelman as managing member.
X4 Pharmaceuticals, Inc. filed an amended current report to correct a typographical error in a prior disclosure about its Class III director nominees, confirming that Murray W. Stewart, M.D. was elected rather than Michael S. Wyzga. The filing also reports final voting results from the May 11, 2026 annual stockholder meeting.
Stockholders approved increasing the shares available under the Second Amended and Restated 2017 Equity Incentive Plan by 1,500,000 shares and ratified PricewaterhouseCoopers LLP as independent auditor for the year ending December 31, 2026. They also approved, on a non-binding basis, the compensation of the company’s named executive officers.
X4 Pharmaceuticals Chief Financial Officer David Kirske reported an open-market sale of common stock. On May 12, 2026, he sold 16,961 shares of X4 Pharmaceuticals stock at a weighted average price of $4.2934 per share. According to the footnotes, this sale was made to cover a personal income tax obligation arising from the settlement of a restricted stock unit award, making it a largely tax-driven transaction rather than a discretionary portfolio move. After the sale, Kirske directly owned 176,293 shares, of which 128,836 shares are in the form of restricted stock units, so he continues to hold a substantial equity stake in the company.
X4 Pharmaceuticals, Inc. reported results of its annual stockholder meeting. Stockholders approved the Second Amended and Restated 2017 Equity Incentive Plan, adding 1,500,000 shares to the pool available for equity awards. As of March 13, 2026, there were 90,919,696 common shares outstanding and entitled to vote.
Three Class III directors—Gary J. Bridger, Ph.D., Françoise De Craecker, and Michael S. Wyzga—were elected to serve until the 2029 annual meeting. Stockholders also ratified PricewaterhouseCoopers LLP as independent registered public accounting firm for the year ending December 31, 2026 and approved, on a non-binding basis, the compensation of the named executive officers.
X4 Pharmaceuticals filed a shelf registration on Form S-3 to offer up to $300,000,000 of securities, including common stock, preferred stock, debt securities, warrants and/or units. The filing includes an at-the-market sales agreement with Jefferies to sell up to $75,000,000 of common stock.
The prospectus discloses that X4 has one approved product, XOLREMDI® (mavorixafor), and is conducting a global Phase 3 4WARD trial in chronic neutropenia targeting up to 176 patients with full enrollment aimed for the end of Q3 2026. The base prospectus and any prospectus supplement will specify terms and intended uses of proceeds.
X4 Pharmaceuticals reported a Q1 2026 net loss of $20.2 million, reversing a small profit a year earlier as prior-year one-time license revenue from Norgine did not repeat. Total revenue was $2.7 million, including $2.5 million of U.S. XOLREMDI product sales and $0.2 million from its Norgine license.
Research and development expenses were $15.5 million and general and administrative expenses were $6.9 million, both down sharply following 2025 restructuring. X4 ended March 31, 2026 with $233.7 million in cash, cash equivalents and short-term marketable securities and $75.0 million of Hercules term debt.
During the quarter, X4 continued enrolling its global Phase 3 4WARD trial of mavorixafor in chronic neutropenia. On April 29, 2026, after quarter-end, the European Commission granted marketing authorization for XOLREMDI capsules to treat patients with WHIM syndrome in the European Union.
X4 Pharmaceuticals files its 2025 Annual Report on Form 10-K. The company describes its business as a developer and commercializer of novel therapeutics for rare hematology diseases, with one FDA‑approved product, XOLREMDI® (mavorixafor), for WHIM syndrome.
Highlights include a 1‑for‑30 reverse stock split, $253.0 million in cash, cash equivalents and marketable securities as of December 31, 2025, net proceeds of $81.0 million from an August 2025 PIPE and $145.6 million from a fourth‑quarter 2025 public offering, and 90,919,696 shares outstanding as of March 12, 2026. The company is conducting the global Phase 3 4WARD trial in chronic neutropenia, targeting full enrollment of 176 patients in the third quarter of 2026 with top‑line data expected in the second half of 2027. The EMA’s CHMP adopted a positive opinion in February 2026, with an EC final decision anticipated in the second quarter of 2026.
X4 Pharmaceuticals, Inc. is asking stockholders to vote at its virtual 2026 annual meeting on May 11, 2026. The agenda includes electing three Class III directors to serve until 2029, ratifying PricewaterhouseCoopers LLP as auditor for 2026, approving an amended 2017 Equity Incentive Plan that adds 1,500,000 shares for employee and director awards, and a non-binding advisory vote on executive pay. Stockholders of record on March 13, 2026, when 90,919,696 common shares were outstanding, can vote online or by proxy. The proxy describes board structure, committee responsibilities, governance policies, and how compensation and equity awards are determined.